New immune therapy combo aims to tame chronic GVHD in Steroid-Resistant patients
NCT ID NCT01937468
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests the safety of combining donor anti-inflammatory Treg cells with low-dose Interleukin-2 (IL-2) for people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a complication after a stem cell or bone marrow transplant where the donor's immune cells attack the recipient's body. The study enrolls 25 participants and aims to find the safest dose of this combination, which may help control the immune attack without the need for high-dose steroids.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Regulatory T-cells (Treg) and low-dose Interleukin-2 (IL-2)
- What this could lead to
- If this works, it could point toward a new way to control chronic GVHD without high-dose steroids, helping patients who have not responded to standard treatment.
- What could go wrong
- This is a very early phase I trial with only 25 participants, focused on safety and dosing. It may not show clear benefit, and there are risks from the cell infusion and IL-2, including immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Insitute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Could a liquid form of a Graft-Versus-Host disease drug be as effective as the pill?
- Scientists map immune battlefield in chronic GVHD tissue
- Could a rheumatoid arthritis drug tame chronic GVHD and cut steroid use?
- Could an arthritis drug tame a tough transplant complication?
- New hope for teens with chronic Graft-Versus-Host disease: belumosudil under study